Mainz Biomed N.V.
Open
$1.72
Prev. Close
$1.72
High
$1.72
Low
$1.72
Market Snapshot
$21.65M
-1.0
-54.09
$1.29M
10
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Recently from Cashu
Couldn't load Cashu news
Something went wrong. Try refreshing the page.